CD44v6 high membranous expression is a predictive marker of therapy response in gastric cancer patients
| Autor(a) principal: | |
|---|---|
| Data de Publicação: | 2021 |
| Outros Autores: | , , , , , , , , , , , , , , , , , , |
| Tipo de documento: | Artigo |
| Idioma: | eng |
| Título da fonte: | Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
| Texto Completo: | http://hdl.handle.net/10451/49663 |
Resumo: | © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
| id |
RCAP_172ed2182b2be8837ef59d0217ae407a |
|---|---|
| oai_identifier_str |
oai:repositorio.ul.pt:10451/49663 |
| network_acronym_str |
RCAP |
| network_name_str |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
| repository_id_str |
7160 |
| spelling |
CD44v6 high membranous expression is a predictive marker of therapy response in gastric cancer patientsBiomarkersConventional chemotherapyDrug therapyGastric surgeryGenetic heterogeneityStomach neoplasms© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).In gastric cancer (GC), biomarkers that define prognosis and predict treatment response remain scarce. We hypothesized that the extent of CD44v6 membranous tumor expression could predict prognosis and therapy response in GC patients. Two GC surgical cohorts, from Portugal and South Korea (n = 964), were characterized for the extension of CD44v6 membranous immuno-expression, clinicopathological features, patient survival, and therapy response. The value of CD44v6 expression in predicting response to treatment and its impact on prognosis was determined. High CD44v6 expression was associated with invasive features (perineural invasion and depth of invasion) in both cohorts and with worse survival in the Portuguese GC cohort (HR 1.461; 95% confidence interval 1.002-2.131). Patients with high CD44v6 tumor expression benefited from conventional chemotherapy in addition to surgery (p < 0.05), particularly those with heterogeneous CD44v6-positive and -negative populations (CD44v6_3+) (p < 0.007 and p < 0.009). Our study is the first to identify CD44v6 high membranous expression as a potential predictive marker of response to conventional treatment, but it does not clarify CD44v6 prognostic value in GC. Importantly, our data support selection of GC patients with high CD44v6-expressing tumors for conventional chemotherapy in addition to surgery. These findings will allow better stratification of GC patients for treatment, potentially improving their overall survival.This work was funded by FEDER-Fundo Europeu de Desenvolvimento Regional funds through the COMPETE 2020–Operacional Programme for Competitiveness and Internationalization (POCI), Portugal 2020, and by Portuguese funds through FCT–Fundação para a Ciência e a Tecnologia/Ministério da Ciência, Tecnologia e Inovação in the framework of the project “Institute for Research and Innovation in Health Sciences” (POCI-01-0145-FEDER-007274). This work was also financed by the projects NORTE-01-0145-FEDER-000003 and NORTE-01-0145-FEDER-000029, supported by the Norte Portugal Regional Programme (NORTE 2020) under the PORTUGAL 2020 Partnership Agreement, through the European Regional Development Fund (ERDF); project POCI-01-0145-FEDER-016390 and SAICTPAC/0022/2015, funded by ERDF, POCI, and FCT; project PTDC/CTM-NAN/120958/2010, from FCT; and by project PTDC/BTM-TEC/30164/2017 funded by ERDF funds through the COMPETE 2020–POCI, Portugal 2020, and by FCT. Salary support to G.M.A. by PTDC/BTM-TEC/30164/2017 project; C.P. was supported by the grant SFRH/BD/113031/2015 from FCT.MDPIRepositório da Universidade de LisboaAlmeida, Gabriela MPereira, CarlaPark, Ji-HyeonLemos, CarolinaCampelos, SofiaGullo, IreneMartins, DianaGonçalves, GilzaLeitão, DinaNeto, João LuísAndré, AnaBorges, ClaraAlmeida, DanielaLee, Hyuk-JoonKong, Seong-HoKim, Woo HoCarneiro, FátimaAlmeida, RaquelYang, Han-KwangOliveira, Carla2021-09-28T14:45:28Z20212021-01-01T00:00:00Zinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfhttp://hdl.handle.net/10451/49663engBiomedicines. 2021 Sep 18;9(9):124910.3390/biomedicines90912492227-9059info:eu-repo/semantics/openAccessreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAP2023-11-08T16:53:37Zoai:repositorio.ul.pt:10451/49663Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-19T22:01:18.186827Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse |
| dc.title.none.fl_str_mv |
CD44v6 high membranous expression is a predictive marker of therapy response in gastric cancer patients |
| title |
CD44v6 high membranous expression is a predictive marker of therapy response in gastric cancer patients |
| spellingShingle |
CD44v6 high membranous expression is a predictive marker of therapy response in gastric cancer patients Almeida, Gabriela M Biomarkers Conventional chemotherapy Drug therapy Gastric surgery Genetic heterogeneity Stomach neoplasms |
| title_short |
CD44v6 high membranous expression is a predictive marker of therapy response in gastric cancer patients |
| title_full |
CD44v6 high membranous expression is a predictive marker of therapy response in gastric cancer patients |
| title_fullStr |
CD44v6 high membranous expression is a predictive marker of therapy response in gastric cancer patients |
| title_full_unstemmed |
CD44v6 high membranous expression is a predictive marker of therapy response in gastric cancer patients |
| title_sort |
CD44v6 high membranous expression is a predictive marker of therapy response in gastric cancer patients |
| author |
Almeida, Gabriela M |
| author_facet |
Almeida, Gabriela M Pereira, Carla Park, Ji-Hyeon Lemos, Carolina Campelos, Sofia Gullo, Irene Martins, Diana Gonçalves, Gilza Leitão, Dina Neto, João Luís André, Ana Borges, Clara Almeida, Daniela Lee, Hyuk-Joon Kong, Seong-Ho Kim, Woo Ho Carneiro, Fátima Almeida, Raquel Yang, Han-Kwang Oliveira, Carla |
| author_role |
author |
| author2 |
Pereira, Carla Park, Ji-Hyeon Lemos, Carolina Campelos, Sofia Gullo, Irene Martins, Diana Gonçalves, Gilza Leitão, Dina Neto, João Luís André, Ana Borges, Clara Almeida, Daniela Lee, Hyuk-Joon Kong, Seong-Ho Kim, Woo Ho Carneiro, Fátima Almeida, Raquel Yang, Han-Kwang Oliveira, Carla |
| author2_role |
author author author author author author author author author author author author author author author author author author author |
| dc.contributor.none.fl_str_mv |
Repositório da Universidade de Lisboa |
| dc.contributor.author.fl_str_mv |
Almeida, Gabriela M Pereira, Carla Park, Ji-Hyeon Lemos, Carolina Campelos, Sofia Gullo, Irene Martins, Diana Gonçalves, Gilza Leitão, Dina Neto, João Luís André, Ana Borges, Clara Almeida, Daniela Lee, Hyuk-Joon Kong, Seong-Ho Kim, Woo Ho Carneiro, Fátima Almeida, Raquel Yang, Han-Kwang Oliveira, Carla |
| dc.subject.por.fl_str_mv |
Biomarkers Conventional chemotherapy Drug therapy Gastric surgery Genetic heterogeneity Stomach neoplasms |
| topic |
Biomarkers Conventional chemotherapy Drug therapy Gastric surgery Genetic heterogeneity Stomach neoplasms |
| description |
© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
| publishDate |
2021 |
| dc.date.none.fl_str_mv |
2021-09-28T14:45:28Z 2021 2021-01-01T00:00:00Z |
| dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
| dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
| format |
article |
| status_str |
publishedVersion |
| dc.identifier.uri.fl_str_mv |
http://hdl.handle.net/10451/49663 |
| url |
http://hdl.handle.net/10451/49663 |
| dc.language.iso.fl_str_mv |
eng |
| language |
eng |
| dc.relation.none.fl_str_mv |
Biomedicines. 2021 Sep 18;9(9):1249 10.3390/biomedicines9091249 2227-9059 |
| dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
| eu_rights_str_mv |
openAccess |
| dc.format.none.fl_str_mv |
application/pdf |
| dc.publisher.none.fl_str_mv |
MDPI |
| publisher.none.fl_str_mv |
MDPI |
| dc.source.none.fl_str_mv |
reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação instacron:RCAAP |
| instname_str |
Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação |
| instacron_str |
RCAAP |
| institution |
RCAAP |
| reponame_str |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
| collection |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
| repository.name.fl_str_mv |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação |
| repository.mail.fl_str_mv |
|
| _version_ |
1799134560868368384 |